No exosome-based hair-loss product has FDA approval. Clinical trials in the USA are investigational; some operate under IND protocols or as commercial clinical studies outside the FDA formal pathway. European trials are registered but operate as investigational medical procedures. Regulatory pathways for cosmetic/medical classification remain unsettled; approval timelines are uncertain.
Androgenetic alopecia and other hair-loss conditions result from follicle miniaturisation, stem-cell exhaustion within the dermal papilla, and inflammatory signalling that disrupts the hair growth cycle. Exosomes derived from umbilical-cord fibroblasts and mesenchymal stem cells contain growth factors (bFGF, VEGF, HGF), microRNAs (miR-29b regulating collagen cross-linking), and lipid mediators that promote angiogenesis, collagen deposition, and hair-follicle neogenesis in preclinical models. Sixteen registered clinical trials and four actively recruiting studies assess topical, intradermal, and systemic exosome formulations alongside platelet-rich plasma and conventional minoxidil or finasteride regimens.
Am I a candidate? → · Hair Loss & Restoration: full overview → · Hair Loss & Restoration cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita